| __timestamp | BeiGene, Ltd. | PTC Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 21862000 | 79838000 |
| Thursday, January 1, 2015 | 58250000 | 121816000 |
| Friday, January 1, 2016 | 98033000 | 117633000 |
| Sunday, January 1, 2017 | 273992000 | 4577000 |
| Monday, January 1, 2018 | 707710000 | 12670000 |
| Tuesday, January 1, 2019 | 998528000 | 12135000 |
| Wednesday, January 1, 2020 | 1365534000 | 18942000 |
| Friday, January 1, 2021 | 1624145000 | 32328000 |
| Saturday, January 1, 2022 | 1926983000 | 44678000 |
| Sunday, January 1, 2023 | 379920000 | 65486000 |
Unleashing the power of data
In the dynamic world of biotechnology, understanding the cost of revenue is crucial for evaluating a company's financial health. BeiGene, Ltd. and PTC Therapeutics, Inc., two prominent players in the industry, offer a fascinating case study. From 2014 to 2023, BeiGene's cost of revenue surged by an astounding 8,700%, peaking in 2022. This growth reflects its aggressive expansion and investment in research and development. In contrast, PTC Therapeutics experienced a more modest increase of 18% over the same period, indicating a more conservative approach. Notably, 2023 saw a significant drop in BeiGene's cost of revenue, suggesting a strategic shift or operational efficiency improvements. This comparative analysis highlights the diverse strategies within the biotech sector, offering valuable insights for investors and industry enthusiasts alike.
Cost Insights: Breaking Down Novo Nordisk A/S and BeiGene, Ltd.'s Expenses
Cost of Revenue Trends: Pfizer Inc. vs PTC Therapeutics, Inc.
Cost of Revenue Trends: Sanofi vs BeiGene, Ltd.
Cost of Revenue Trends: Bristol-Myers Squibb Company vs BeiGene, Ltd.
BeiGene, Ltd. vs Intra-Cellular Therapies, Inc.: Efficiency in Cost of Revenue Explored
BeiGene, Ltd. vs Pharming Group N.V.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down BeiGene, Ltd. and Dyne Therapeutics, Inc.'s Expenses
Cost of Revenue Trends: United Therapeutics Corporation vs PTC Therapeutics, Inc.
Cost of Revenue: Key Insights for Halozyme Therapeutics, Inc. and PTC Therapeutics, Inc.
Cost Insights: Breaking Down PTC Therapeutics, Inc. and Perrigo Company plc's Expenses
PTC Therapeutics, Inc. vs HUTCHMED (China) Limited: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for PTC Therapeutics, Inc. and Dyne Therapeutics, Inc.